November 26, 2016

AngioSoma Research Inc.

[dropcap]A[/dropcap]ngioSoma, Inc. has a robust product pipeline, with patents, provisional patents, expired patents with corporate intellectual property / knowledge, registered trademarks, and many more to come. AngioSoma’s aggressive mission objective research efforts have led to the company’s most important current corporate assets that contribute to the shareholder value.

Products in Pipeline


Liprostin™, AngioSoma, Inc.’s flagship product in its product pipeline, is a Peripheral Artery Disease (‘PAD‘) therapy using FDA approved Alprostadil™ (a prostaglandin, referred to as PGE-1) packaged inside a proprietary Liposome for controlled drug release. Learn More…


Transdermal PGE-1 Patch

In September 2016, AngioSoma, Inc. with its Chairman Emeritus David P. ‘Doc‘ Summers PhD filed 2 provisional U.S. Patents and 2 non-provisional U.S. Patents (announced October 11, 2016 in a press release entitled ‘AngioSoma, Inc. Files 3 New Patent Applications on Liprostin™). Learn More…



OmniCath I & OmniCath II

AngioSoma, Inc., a publicly traded Nevada corporation (‘SOAN’), and its subsidiary AngioSoma Research, Inc., a wholly owned Texas subsidiary, own patents associated with the OmniCath® I atherectomy catheter, protected by a U.S. Patent 5,728,129 issued on March 17th, 1998. SOAN is filing new patents currently which will, in conjunction with the original base patent, create the OmniCath® II. Learn More…



SOMA Nutraceuticals, Inc.

SOMA Nutraceuticals, Inc., a Texas wholly owned subsidiary of AngioSoma, Inc., provides nutraceutical products, both patented and proprietary formulated, that integrate fully into AngioSoma, Inc.’s mission statement of having a complete solution for the treatment of cardiovascular disease – prior to the need for treatment to prevent the need for treatment (SOMA Nutraceuticals, Inc.), at treatment to bring patients up to a foundational level (Liprostin™ and the OmniCath I & II), and once patients have gotten to a foundational level to keep them at that level (the Transdermal PGE-1 Patch). Learn More…